Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.
Publication
, Journal Article
Ajani, JA; Abbruzzese, JL; Markowitz, AB; Patt, YZ; Daugherty, K
Published in: Invest New Drugs
February 1993
Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.
Duke Scholars
Published In
Invest New Drugs
DOI
ISSN
0167-6997
Publication Date
February 1993
Volume
11
Issue
1
Start / End Page
67 / 69
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasm Metastasis
- Middle Aged
- Male
- Interferon-alpha
- Humans
- Female
- Etoposide
- Drug Synergism
- Colorectal Neoplasms
Citation
APA
Chicago
ICMJE
MLA
NLM
Ajani, J. A., Abbruzzese, J. L., Markowitz, A. B., Patt, Y. Z., & Daugherty, K. (1993). Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs, 11(1), 67–69. https://doi.org/10.1007/BF00873914
Ajani, J. A., J. L. Abbruzzese, A. B. Markowitz, Y. Z. Patt, and K. Daugherty. “Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.” Invest New Drugs 11, no. 1 (February 1993): 67–69. https://doi.org/10.1007/BF00873914.
Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs. 1993 Feb;11(1):67–9.
Ajani, J. A., et al. “Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.” Invest New Drugs, vol. 11, no. 1, Feb. 1993, pp. 67–69. Pubmed, doi:10.1007/BF00873914.
Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs. 1993 Feb;11(1):67–69.
Published In
Invest New Drugs
DOI
ISSN
0167-6997
Publication Date
February 1993
Volume
11
Issue
1
Start / End Page
67 / 69
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasm Metastasis
- Middle Aged
- Male
- Interferon-alpha
- Humans
- Female
- Etoposide
- Drug Synergism
- Colorectal Neoplasms